NCT06929910Recruiting
Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.
Evaluation of Systemic Therapy and the Effectiveness of Circulating Tumor DNA (ctDNA) Assays in Monitoring Treatment Response in Patients With Metastatic Cancer Undergoing K4Care Testing
Source: ClinicalTrials.gov · Last updated 16 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to investigate the real-world treatment landscape of patients with metastatic cancer and determine the role of ctDNA in monitoring treatment response in patients with metastatic cancer who have undergone K4Care testing
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 8 Apr 2025
- Start date
- 9 Apr 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Gene Solutions
- Diseases
- Childhood cancers
- NCT number
- NCT06929910
What you commit to
- Study type: Observational
- Planned participants: 200
- From 9 Apr 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Absence of prior K4Care testing.
Other illness
- Diagnosis of early-stage cancer or hematologic malignancy.
Other
- Refusal to participate in the study.
- Refusal to provide clinical information or blood samples.
Who the study is looking for
- Pathological and imaging confirmation of metastatic or progressive stage IV cancer.
- Consent to the use of their clinical data.
- Diagnosis of one of the following common solid tumor types: lung, colorectal, breast, gastric, or cancer of unknown primary origin.
- Prior K4Care testing to identify tumor tissue (FFPE) mutations and consent to the use of their sequencing data.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical Genetics Institute Coordinator of this site? Confirm its status | Ho Chi Minh City | Vietnam | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.